Aclaris Therapeutics, Inc.
Compare this stock
ACRS Stock Report Card
$
35%
Performance
Score:
10/100
ACRS returned -96.22% in the last 12 months. Based on SPY's performance of -11.17%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
92/100
6 analysts offer 12-month price targets for ACRS. Together, they have an average target of 25, the most optimistic target put ACRS at 25 within 12-months and the most pessimistic has ACRS at 25.
Sentiment
Score:
69/100
ACRS had a bullish sentiment score of 68.61% across Twitter and StockTwits over the last 12 months. It had an average of 32.27 posts, 12.68 comments, and 65.86 likes per day.
Technicals
Score:
14/100
ACRS receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
Score:
10/100
ACRS has missed earnings 8 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, ACRS has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
42/100
ACRS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.
Aclaris Therapeutics, Inc. Summary
Nasdaq / ACRS
Healthcare
Medical - Diagnostics & Research
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ACRS scored poorly on our reportcard. Here are some similar companies and how they performed.
